Actively Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
Led by LaNova Medicines Limited · Updated on 2025-09-09
49
Participants Needed
6
Research Sites
158 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
CONDITIONS
Official Title
A Study of LM-24C5 For Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Fully informed and willing to participate with signed consent
- Age 18 years or older
- ECOG performance status of 0 or 1 with no recent decline
- Life expectancy of at least 3 months
- Histological or cytological confirmation of recurrent or refractory advanced solid tumors
- Tumor tissue samples available meeting minimum requirements
- At least one measurable lesion per RECIST v1.1
- Adequate organ and marrow function within 7 days prior to first dose
- Able to communicate well and follow study requirements
You will not qualify if you...
- Participation in another clinical trial within 28 days before first dose
- Prior treatments targeting the investigational target
- Anti-tumor treatment within 21 days before first dose
- Unresolved adverse events from prior therapy above grade 1
- Uncontrolled pain
- Known central nervous system or meningeal metastasis
- Uncontrolled pleural, pericardial effusion, or ascites needing drainage
- Severe hypersensitivity to monoclonal antibodies
- Use of systemic corticosteroids or immunosuppressive meds within 2 weeks before first dose
- History of autoimmune disease
- History or evidence of active pneumonitis or related lung conditions
- Use of live vaccines within 28 days before first dose
- Use of therapeutic anticoagulants for active thromboembolic disease
- Major surgery or interventional treatment within 28 days before first dose
- Severe cardiovascular disease
- Uncontrolled or severe illness including active infection
- History of immunodeficiency or organ/bone marrow transplantation
- Active infections such as HIV, tuberculosis, HBV, or HCV (with exceptions)
- Other active malignancies likely to require treatment
- Positive pregnancy test or lactating females with child-bearing potential
- Psychiatric illness affecting study compliance
- Investigator judgment of ineligibility for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
University of Southern California (USC) - Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90089
Not Yet Recruiting
2
Ocala Oncology
Ocala, Florida, United States, 34474
Actively Recruiting
3
Indiana University Melvan and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
Not Yet Recruiting
4
The Christ Hospital
Cincinnati, Ohio, United States, 45219
Not Yet Recruiting
5
Mary Crowley Cancer Research Center
Dallas, Texas, United States, 75230
Not Yet Recruiting
6
Virginia Cancer Specialists, P.C.
Fairfax, Virginia, United States, 22031
Not Yet Recruiting
Research Team
A
Alex Yuan
CONTACT
P
Paul Kong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here